• Cambrian Bio will present results from two Phase 1 studies of ATX-304 at ObesityWeek on November 14, 2026.
• The findings highlight weight-independent metabolic effects, including increased fat mobilization and energy expenditure, building on clinical results presented earlier this year.
• Phase 2 studies are being prepared for patients with obesity or overweight, positioning ATX-304 as a potential complement to appetite-suppressing therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cambrian BioPharma Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.